In a recent pooled analysis of 2932 patients with atopic dermatitis [15], dupilumab (anti-IL-4/13) was not associated with an increased risk of infection compared to placebo, and reductions in severe infections and non-herpetic skin infections were also reported. The gene discussed is IL4; the disease is infection.